Treatment of heart failure with preserved ejection fraction
The treatment of diastolic dysfunction in a subject and, in particular, compositions for use and methods in treating diastolic dysfunction are disclosed. In one aspect, the disclosure provides a composition for use comprising a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject. In particular, the composition for use according to the disclosure comprises a therapeutically effective amount of the alpha B crystalline protein. It was found that the composition for use is capable of treating diastolic dysfunction and diastolic heart disease in subjects with failing hearts that have a higher cardiomyocyte stiffness than controls. Particularly, addition of alpha B crystalline reduced the higher stiffness of failing cardiomyocytes to the level observed in control cardiomyocytes.
1. A method of treating a subject for heart failure with preserved ejection fraction (HFpEF) characterized by diastolic dysfunction caused by diastolic stiffness of cardiomyocytes and interstitial collagen deposition, the method comprising:
administering to the subject a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject,
wherein the substance is geranylgeranylacetone (GGA) or NYK9354.
2. The method according to claim 1 , wherein the crystalline protein is alpha B-crystallin.
3. The method according to claim 2 , wherein the therapeutically effective amount further reduces diastolic stiffness of cardiomyocytes in the subject.
4. A method for treating a subject for heart failure with preserved ejection fraction (HFpEF) characterized by diastolic dysfunction caused by diastolic stiffness of cardiomyocytes and interstitial collagen deposition, or for aortic stenosis, or is at risk of developing said heart failure or said aortic stenosis, the method comprising:
administering to the subject a composition comprising a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in the subject's cardiomyocytes,
wherein the substance is geranylgeranylacetone (GGA) or NYK9354.
5. The method according to claim 4 , wherein the crystalline protein is a protein encoded by the crystallin alpha B (CRYAB) gene.
6. The method according to claim 5 , wherein the substance mediates a post-translational modification of alpha-crystallin B chain.
7. The method according to claim 6 , wherein the substance mediates the post-translational modification of alpha-crystallin B chain by phosphorylation of alpha-crystallin B chain.
8. The method according to claim 4 , wherein the substance increases the level of alpha-crystallin B chain in cardiomyocytes of the subject.
9. The method according to claim 8 , wherein the substance induces expression of the CRYAB gene in the cardiomyocytes of the subject.
10. The method according to claim 4 , wherein the substance mediates a post-translational modification of alpha-crystallin B chain.
11. The method according to claim 10 , wherein the substance mediates the post-translational modification of alpha-crystallin B chain by phosphorylation of alpha-crystallin B chain.